MicroRNA Microarray Analysis of Human Adrenocortical Tumors Identifies miR-195 and miR-483-5p as Predictors of Poor Prognosis in Adrenocortical Cancer – Response

We thank Dr. Tömöl and colleagues for their interest in our article and their comments. As with our study, Dr. Tömöl and colleagues also performed microRNA (miRNA) profiling of adrenocortical tumors. There were however only two miRNAs in common between the two studies. This is, of course, usual in these sort of studies. For example, in the gene expression profiling studies differentiating adrenocortical carcinomas (ACC) and adenomas (ACAs; refs. 1–4), only insulin-like growth factor 2 has been found to be common across all the studies.

Dr. Tömöl and colleague’s study included 19 ACAs and 7 ACCs, which is a small number of ACCs. No clinical follow-up was provided so the influence of miRNA expression on prognosis could not be assessed. They only included functioning ACCs and question our lack of subdivision of ACCs based on functional status, as this may affect miRNA profiles. We had compared the miRNA expression profile of functioning ACCs (n = 11) to nonfunctioning ACCs (n = 9) and found no significantly differentially expressed miRNAs between the two groups. We therefore felt that it was justified to group both functioning and nonfunctioning ACCs together. We also found that significantly differentially expressed miRNAs between ACAs and all ACCs, all ACAs and functioning ACCs, and all ACAs and nonfunctioning ACCs, were similar.

In our study, normal adrenal cortices were obtained from adrenalectomy specimens away from the site of the ACA as has been done in several previous studies (1, 5). It is possible, as Dr. Tömöl and colleagues suggest, that this may account for the low number of miRNAs significantly differentially expressed between adrenocortical tumors and normal adrenal cortices, although we think this is unlikely. In any case, the use of normal adrenal cortex as an external control does not, of course, in any way alter the results obtained comparing the miRNA expression of ACCs and ACAs. Nor does it alter our other key finding that aberrant expression of miR-195 and miR-483-5p portends a poor prognosis in ACCs.

Patsy S.H. Soon
Lyndal J. Tacon
Roderick J. Clifton–Bligh
Bruce G. Robinson
Stan B. Sidhu
Cancer Genetics, Kolling Institute of Medical Research and University of Sydney, Sydney, Australia

Lyndal J. Tacon
Roderick J. Clifton–Bligh
Bruce G. Robinson
Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia

Anthony J. Gill
Department of Anatomical Pathology, Royal North Shore Hospital, and University of Sydney, Sydney, Australia

Christopher P. Bambach
Mark S. Sywak
Stan B. Sidhu
University of Sydney Endocrine Surgical Unit, Royal North Shore Hospital, Sydney, Australia

Peter R. Campbell
Department of Surgery, Liverpool Hospital, Sydney, Australia

Michael W. Yeh
Endocrine Surgical Unit, University of California Los Angeles, Los Angeles, California

Steven G. Wong
Department of Medicine, Division of Hematology and Oncology, University of California at Los Angeles School of Medicine, Los Angeles, California

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References


MicroRNA Microarray Analysis of Human Adrenocortical Tumors Identifies miR-195 and miR-483-5p as Predictors of Poor Prognosis in Adrenocortical Cancer – Response


*Clin Cancer Res* 2010;16:2915-2916. Published OnlineFirst May 11, 2010.

**Updated version**

Access the most recent version of this article at:

doi:10.1158/1078-0432.CCR-10-0594

**Cited articles**

This article cites 5 articles, 3 of which you can access for free at:

http://clincancerres.aacrjournals.org/content/16/10/2915.2.full#ref-list-1

**E-mail alerts**

Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.